CollPlant Biotechnologies’ (CLGN) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a report released on Wednesday morning,Benzinga reports. The brokerage currently has a $14.00 price objective on the stock.

Other equities research analysts also recently issued reports about the company. EF Hutton Acquisition Co. I upgraded CollPlant Biotechnologies to a “strong-buy” rating in a research report on Monday, August 5th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of CollPlant Biotechnologies in a research note on Wednesday, August 21st.

CollPlant Biotechnologies Trading Up 5.4 %

CLGN stock opened at $4.48 on Wednesday. The firm’s 50-day moving average is $4.29 and its two-hundred day moving average is $4.84. The company has a market capitalization of $51.30 million, a price-to-earnings ratio of -2.76 and a beta of 0.44. CollPlant Biotechnologies has a 52 week low of $3.31 and a 52 week high of $6.99.

Institutional Trading of CollPlant Biotechnologies

A number of large investors have recently added to or reduced their stakes in the business. Villere ST Denis J & Co. LLC lifted its position in shares of CollPlant Biotechnologies by 24.4% during the 3rd quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock valued at $2,407,000 after acquiring an additional 95,000 shares during the last quarter. Benjamin Edwards Inc. acquired a new stake in shares of CollPlant Biotechnologies during the third quarter worth $112,000. Finally, Pinnacle Associates Ltd. raised its position in shares of CollPlant Biotechnologies by 6.4% during the second quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock worth $2,805,000 after purchasing an additional 33,905 shares during the period. 21.69% of the stock is currently owned by institutional investors.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.